suPAR has excellent prognostic utility in predicting severe COVID-19 complications

Wed Apr 14 2021

Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) Associate with Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study

Published in the International Journal of Infectious Diseases

A brand new study discloses that suPAR has excellent prognostic utility in predicting severe COVID-19 complications in hospitalized patients.

The ongoing pandemic exerts continuous pressure on hospitals. The current standard of care for triaging COVID-19 patients relies on routine clinical and laboratory assessment but offers limited prognostic information.

The study’s results demonstrate that COVID-19 patients with increased baseline suPAR levels are at a high risk of developing complications, which can significantly improve COVID-19 triage. It is essential to correctly identify patients that may be safely discharged home, those who need hospitalization, and those at risk of deterioration, potentially requiring ICU admission.

Highlights:

  • suPAR has been suggested as a good prognosis for severe complications of COVID-19.
  • COVID-19 patients with increased suPAR are at high risk of developing complications
  • Increasing suPAR by 1 ng/mL leads to 58% rise in the risk of getting complications.

suPAR has excellent prognostic utility in predicting severe COVID-19 complications

– Oulhaj et al, International Journal of Infectious Diseases, April 2021

Read the study here

+800

published suPAR studies in leading medical journals

The suPARnostic® brand consists of 3 products:

Photo of The suPARnostic® Quick Triage kit

Quick Triage

A Point of Care Solution

Photo of suPARnostic® TurbiLatex

TurbiLatex

For Automated Systems

Photo of suPARnostic® ELISA

ELISA Assay

Clinical and Research

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates